Marchetti C, et al. - Authors here aimed at determining the efficacy and tolerability of trabectedin given every 10 days as a single agent in recurrent ovarian cancer after 3 prior regimens. They recognized that single-agent trabectedin every 10 days was an active treatment with a manageable toxicity profile in heavily pretreated advanced relapsed ovarian cancer patients.